EQUITY RESEARCH MEMO
Healgen Scientific
Generated 5/11/2026
Executive Summary
Conviction (model self-assessment)55/100
Healgen Scientific is a Houston-based diagnostics company specializing in FDA-cleared rapid tests for infectious diseases and drug abuse. Founded in 2007, the company offers products such as the Healgen® Rapid Check® COVID-19/Flu A&B Antigen Test, Accurate Fentanyl Rapid Tests, and multi-drug urine screens for both professional and home use. With a focus on point-of-care and at-home testing, Healgen aims to address critical public health needs including respiratory infections and the opioid crisis. As a private company, Healgen operates with a lean profile but has established a foothold in the diagnostics market through regulatory clearances and a broad product portfolio.
Upcoming Catalysts (preview)
- Q3 2026Expansion of COVID-19/Flu A&B Test Distribution70% success
- Q4 2026FDA 510(k) Clearance for New Drug Test Panel60% success
- Q2 2026Partnership with National Retail Pharmacy Chain50% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)